The ScyFIX 700 therapy uses microcurrent neuromodulation that generates a tiny current of electricity to stimulate the body’s own healing capabilities. This is the first-ever device therapy approval for Retinitis Pigmentosa (RP), a degenerative disease where peripheral vision is lost that can lead to total blindness. Additional approvals for the treatment of other blindness-related diseases are expected soon, including AMD.
The ScyFIX 700 works by administering a tiny current of electricity that stimulates the body’s own healing capabilities. ScyFIX, based in Minneapolis, Minn., has developed the technology over the past seven years. A video describing the ScyFIX 700 system is available at http://www.onemedplace.com/database/list/cid/9896/. More information is also available on www.scyfix.org.